Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (DE:LLY)
XETRA:LLY
Holding DE:LLY?
Track your performance easily
LLY Stock Chart & Stats
Day’s Range― - ―
52-Week Range€568.00 - €885.30
Previous CloseN/A
Volume143.00
Average Volume (3M)3.40K
Market Cap
$697.23B
Enterprise Value€829.46B
Total Cash (Recent Filing)$6.04B
Total Debt (Recent Filing)$8.37B
Price to Earnings (P/E)87.5
Beta0.15
Next Earnings
Feb 06, 2025EPS Estimate
5.14Next Dividend Ex-Date
Feb 14, 2025Dividend Yield0.69%
Share Statistics
EPS (TTM)8.46
Shares Outstanding949,315,700
10 Day Avg. Volume2,651
30 Day Avg. Volume3,402
Standard Deviation0.09
R-Squared0.00581
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.60
Price to Cash Flow (P/CF)48.40
P/FCF Ratio76.20
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue20.30
Enterprise Value/Gross Profit30.67
Enterprise Value/Ebitda67.32
Forecast
1Y Price Target
€993.71Price Target Upside38.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
Financial Performance And GuidanceThe 2025 guide provides a counter to the 2024 cut, with more robust growth than Street estimates, driven by improved outlook for additional Lilly launches.
Product Approval And Market ExpansionTirzepatide's US approval for obstructive sleep apnea and its superior results compared to semaglutide are expected to drive significant US growth.
Strategic AcquisitionThe acquisition of Scorpion's PI3Ka is seen as a step in the right direction for LLY Oncology and is considered NPV-positive.
Bears Say
Earnings ReliabilityThe company missed expectations for two quarters in a row, raising questions about the reliability of its guidance.
Guidance CutLilly's management announced a guidance cut for 2024, reducing expected revenue by $700M at the midpoint to ~$45B, driven by lower than expected growth for Mounjaro and Zepbound and lower channel inventory stocking.
Revenue ShortfallQ4 revenues came in lower than estimates, driven by misses in key products Mounjaro and Zepbound.
---
Options Prices
Currently, No data available
---
Ownership Overview
10.35% Insiders
22.59% Mutual Funds
0.17% Other Institutional Investors
50.71% Public Companies and Individual Investors
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was €568.00 and its highest was €885.30 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Eli Lilly & Co’s market cap is $697.23B.
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Feb 06, 2025 which is in 15 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Oct 30, 2024. The company reported €1.146 earnings per share for the quarter, missing the consensus estimate of €1.38 by -€0.234.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of €5.037 which represents an annual dividend yield of 0.69%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is 5.14.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 949,315,700 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of €1.146 in its last earnings report, missing expectations of €1.38. Following the earnings report the stock price went down -7.9%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Currently, no hedge funds are holding shares in DE:LLY
---
Eli Lilly & Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€993.71 (38.09% Upside)
€993.71 (38.09% Upside)
Blogger Sentiment
Bullish
DE:LLY Sentiment 83%
Sector Average 71%
Sector Average 71%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.14%
12-Months-Change
Fundamentals
Return on Equity
65.75%
Trailing 12-Months
Asset Growth
30.55%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and product performance, driven by new product launches and pipeline advancements. However, there were some challenges such as the decline in Trulicity revenue and inventory management issues impacting sales. Despite these, the company's financial health and future prospects remain robust.Read More>---
LLY Revenue Breakdown
63.86% U.S.
18.09% Europe
8.63% Other foreign countries
4.90% Japan
4.51% China
---
LLY Stock 12 Month Forecast
Average Price Target
€993.71
▲(38.09% Upside)
Technical Analysis
Eli Lilly & Co
―
Meta Platforms
―
Johnson & Johnson
―
Nvidia
―
Tesla
―
Berkshire Hathaway B
―
Visa
―
Best Analysts Covering LLY
1 Year
1 Year Success Rate
34/37 ratings generated profit
1 Year Average Return
+37.24%
reiterated a buy rating 8 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 91.89% of your transactions generating a profit, with an average return of +37.24% per trade.
---